Sustainable pharmaceutical product lifecycle management
Sustainability at Orion means balancing social, economical and environmental factors and is a principle built into our common values. We consider these aspects during the entire life cycle of a product – from research and development through to manufacturing to patient use and product end-of-life disposal.
In our R&D activities, our commitment to building well-being means that we develop efficacious and safe medicinal treatments for unmet medical needs, representing innovation and the highest quality standards. We are committed to high ethical standards concerning pharmaceutical research and development.
We conduct environmental, health and safety risk assessments for all new products before manufacturing starts.
Chemicals and raw materials manufacturing and sourcing
Suppliers are required to comply with Good Practices (GxP) requirements, and in addition to this, according to our Supplier Code of Conduct we expect our suppliers to demonstrate their commitment to sustainable and ethical practices. We only purchase our materials from suppliers whose qualifications we have confirmed. We conduct GxP audits into the operations of our GxP critical business partners and suppliers. We always take and analyse samples of raw materials before approving them for production.
We manage and monitor our suppliers’ environmental, health, safety (EHS) and ethical compliance as well. Our risk-based EHS programme conducted 30 EHS on-site audits in 2017.
Product manufacturing / Own factories
We have identified the most significant environmental aspects for the Orion Group and continuously improve our performance in this regard. Among other things, particular emphasis has been placed on continuously improving our waste water handling and focusing on occupational health and safety at our own factories. We are also committed to reaching the energy savings target for 2025, which is 7.5% of energy consumption in 2016. This means a saving of slightly over 12 GWh, 31% of which was achieved in 2017.
Our products are manufactured using qualified production equipment in a controlled production environment using validated production and quality control methods to ensure that each batch fulfils predetermined quality specifications. The data integrity of all manufacturing and quality control activities is reviewed in detail before a batch is released to market. We take immediate action if any deficiency with regards to product quality is detected.
We minimise waste through package design and optimise shelf life, package sizes and material flows. Optimising shelf life is of particular importance to ensure that all the resources needed in manufacturing, packaging and transportation are not wasted.
Safety is important aspect also in packaging. Packaging plays an important role in protecting our products. We are implementing serialisation and tamper evidence features, new safety measures, to improve safety and traceability even further.
Transportation and distribution
In logistics, we use specialist service providers to meet our strict quality and reliability requirements. Our partners have measures in place to reduce their own environmental impact.
We conduct continuous safety monitoring, collect customer feedback and carry out benefit-risk evaluations throughout the entire lifespan of a product.
We also provide healthcare professionals with clear information on the appropriate use of our medicinal products.
Product end of life & disposal
We make sure that waste materials from our own operations are appropriately treated. Unused medicines should be returned to pharmacies to be disposed of appropriately and packaging materials should be taken to dedicated collection points for recycling.